BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl). 2005;181:237-243. [PMID: 15830233 DOI: 10.1007/s00213-005-2234-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol 2011;26:224-36. [PMID: 21671456 DOI: 10.1002/hup.1196] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
2 Metrik J, Kahler CW, McGeary JE, Monti PM, Rohsenow DJ. Acute Effects of Marijuana Smoking on Negative and Positive Affect. J Cogn Psychother 2011;25. [PMID: 24319318 DOI: 10.1891/0889-8391.25.1.31] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
3 Issa MA, Narang S, Jamison RN, Michna E, Edwards RR, Penetar DM, Wasan AD. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. Clin J Pain 2014;30:472-8. [PMID: 24281276 DOI: 10.1097/AJP.0000000000000022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 3.1] [Reference Citation Analysis]
4 Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011;116:142-50. [PMID: 21310551 DOI: 10.1016/j.drugalcdep.2010.12.010] [Cited by in Crossref: 128] [Cited by in F6Publishing: 95] [Article Influence: 12.8] [Reference Citation Analysis]
5 Kollins SH, Schoenfelder EN, English JS, Holdaway A, Van Voorhees E, O'Brien BR, Dew R, Chrisman AK. An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults. J Subst Abuse Treat 2015;48:96-103. [PMID: 25175495 DOI: 10.1016/j.jsat.2014.07.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
6 Brezing CA, Levin FR. Cannabinoids to Treat Cannabis Use Disorders. In: Montoya ID, Weiss SRB, editors. Cannabis Use Disorders. Cham: Springer International Publishing; 2019. pp. 201-5. [DOI: 10.1007/978-3-319-90365-1_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. Pharmacol Biochem Behav 2020;199:173059. [PMID: 33086126 DOI: 10.1016/j.pbb.2020.173059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
8 Zuurman L, Ippel AE, Moin E, van Gerven JM. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol 2009;67:5-21. [PMID: 19133057 DOI: 10.1111/j.1365-2125.2008.03329.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 6.4] [Reference Citation Analysis]
9 Withey SL, Bergman J, Huestis MA, George SR, Madras BK. THC and CBD blood and brain concentrations following daily administration to adolescent primates. Drug Alcohol Depend 2020;213:108129. [PMID: 32593153 DOI: 10.1016/j.drugalcdep.2020.108129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Whitehurst LN, Fogler K, Hall K, Hartmann M, Dyche J. The effects of chronic marijuana use on circadian entrainment. Chronobiol Int 2015;32:561-7. [PMID: 25801606 DOI: 10.3109/07420528.2015.1004078] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Lile JA, Kelly TH, Hays LR. The reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in cannabis users. Behav Pharmacol 2010;21:29-38. [PMID: 19949319 DOI: 10.1097/FBP.0b013e32833470d7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
12 Bossong MG, Jansma JM, van Hell HH, Jager G, Kahn RS, Ramsey NF. Default mode network in the effects of Δ9-Tetrahydrocannabinol (THC) on human executive function. PLoS One 2013;8:e70074. [PMID: 23936144 DOI: 10.1371/journal.pone.0070074] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
13 Fogel JS, Kelly TH, Westgate PM, Lile JA. Sex differences in the subjective effects of oral Δ9-THC in cannabis users. Pharmacol Biochem Behav 2017;152:44-51. [PMID: 26780348 DOI: 10.1016/j.pbb.2016.01.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
14 Lile JA, Kelly TH, Hays LR. Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ⁹-THC in humans discriminating Δ⁹-THC. Drug Alcohol Depend 2014;143:141-8. [PMID: 25124305 DOI: 10.1016/j.drugalcdep.2014.07.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
15 Russo EB. Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. Front Pharmacol 2016;7:309. [PMID: 27683558 DOI: 10.3389/fphar.2016.00309] [Cited by in Crossref: 54] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
16 Lile JA, Kelly TH, Hays LR. Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ9-THC in humans discriminating Δ9-THC. Drug Alcohol Depend 2012;122:61-9. [PMID: 21975195 DOI: 10.1016/j.drugalcdep.2011.09.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
17 Bedi G, Cooper ZD, Haney M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol 2013;18:872-81. [PMID: 22260337 DOI: 10.1111/j.1369-1600.2011.00427.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
18 Cooper ZD, Haney M. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. Drug Alcohol Depend 2009;103:107-13. [PMID: 19443132 DOI: 10.1016/j.drugalcdep.2009.01.023] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 8.3] [Reference Citation Analysis]
19 Lisano JK, Smith JD, Mathias AB, Christensen M, Smoak P, Phillips KT, Quinn CJ, Stewart LK. Performance and Health-Related Characteristics of Physically Active Males Using Marijuana. Journal of Strength and Conditioning Research 2019;33:1658-68. [DOI: 10.1519/jsc.0000000000002238] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
20 Brezing CA, Levin FR. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal. Neuropsychopharmacology 2018;43:173-94. [PMID: 28875989 DOI: 10.1038/npp.2017.212] [Cited by in Crossref: 47] [Cited by in F6Publishing: 24] [Article Influence: 11.8] [Reference Citation Analysis]
21 Cooper ZD, Haney M. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. Int Rev Psychiatry 2009;21:104-12. [PMID: 19367504 DOI: 10.1080/09540260902782752] [Cited by in Crossref: 52] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
22 Solinas M, Yasar S, Goldberg SR. Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res 2007;56:393-405. [PMID: 17936009 DOI: 10.1016/j.phrs.2007.09.005] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 4.6] [Reference Citation Analysis]
23 Luquiens A, Lourenco N, Benyamina A, Aubin HJ. Self-medication of achalasia with cannabis, complicated by a cannabis use disorder. World J Gastroenterol 2015;21:6381-3. [PMID: 26034374 DOI: 10.3748/wjg.v21.i20.6381] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
24 Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug and Alcohol Dependence 2007;86:22-9. [DOI: 10.1016/j.drugalcdep.2006.04.014] [Cited by in Crossref: 110] [Cited by in F6Publishing: 96] [Article Influence: 7.9] [Reference Citation Analysis]
25 Hart CL, Krauss RM. Human drug addiction is more than faulty decision-making. Behav Brain Sci 2008;31:448-9. [DOI: 10.1017/s0140525x08004846] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
26 Hart CL. Increasing treatment options for cannabis dependence: A review of potential pharmacotherapies. Drug and Alcohol Dependence 2005;80:147-59. [DOI: 10.1016/j.drugalcdep.2005.03.027] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
27 Cooper ZD, Haney M. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol 2008;13:188-95. [PMID: 18279497 DOI: 10.1111/j.1369-1600.2007.00095.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
28 Katsidoni V, Kastellakis A, Panagis G. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity. Int J Neuropsychopharmacol 2013;16:2273-84. [PMID: 23830148 DOI: 10.1017/S1461145713000709] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
29 Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. Neuropsychopharmacology 2015;40:2489-98. [PMID: 25881117 DOI: 10.1038/npp.2015.108] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
30 Crane NA, Phan KL. Effect of Δ9-Tetrahydrocannabinol on frontostriatal resting state functional connectivity and subjective euphoric response in healthy young adults. Drug Alcohol Depend 2021;221:108565. [PMID: 33592558 DOI: 10.1016/j.drugalcdep.2021.108565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Lile JA, Kelly TH, Hays LR. Separate and combined effects of the GABA(B) agonist baclofen and Δ9-THC in humans discriminating Δ9-THC. Drug Alcohol Depend 2012;126:216-23. [PMID: 22699093 DOI: 10.1016/j.drugalcdep.2012.05.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
32 Kayser RR, Haney M, Simpson HB. Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research. Front Psychiatry 2021;12:626150. [PMID: 33716825 DOI: 10.3389/fpsyt.2021.626150] [Reference Citation Analysis]
33 Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 2009;56 Suppl 1:235-43. [PMID: 18691603 DOI: 10.1016/j.neuropharm.2008.07.018] [Cited by in Crossref: 61] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
34 Lile JA, Kelly TH, Hays LR. Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC. Drug Alcohol Depend 2011;116:86-92. [PMID: 21227600 DOI: 10.1016/j.drugalcdep.2010.11.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
35 Crippa JAS, Hallak JEC, Machado-de-sousa JP, Queiroz RHC, Bergamaschi M, Chagas MHN, Zuardi AW. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report: CBD and cannabis withdrawal. Journal of Clinical Pharmacy and Therapeutics 2013;38:162-4. [DOI: 10.1111/jcpt.12018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 5.2] [Reference Citation Analysis]
36 Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol and Marijuana in HIV-Positive Marijuana Smokers: Caloric Intake, Mood, and Sleep. JAIDS Journal of Acquired Immune Deficiency Syndromes 2007;45:545-54. [DOI: 10.1097/qai.0b013e31811ed205] [Cited by in Crossref: 98] [Cited by in F6Publishing: 54] [Article Influence: 7.0] [Reference Citation Analysis]
37 Lile JA, Kelly TH, Charnigo RJ, Stinchcomb AL, Hays LR. Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ(9) -THC in cannabis users. J Clin Pharmacol 2013;53:680-90. [PMID: 23754596 DOI: 10.1002/jcph.90] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
38 Justinova Z, Goldberg SR, Heishman SJ, Tanda G. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav 2005;81:285-99. [PMID: 15932767 DOI: 10.1016/j.pbb.2005.01.026] [Cited by in Crossref: 84] [Cited by in F6Publishing: 61] [Article Influence: 5.3] [Reference Citation Analysis]
39 Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A, Chen N, Stoch SA, Wagner J, Chodakewitz J, Sellers EM. Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist: A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study in Recreational Polydrug Users. Journal of Clinical Psychopharmacology 2012;32:492-502. [DOI: 10.1097/jcp.0b013e31825d380d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
40 Wiebelhaus JM, Grim TW, Owens RA, Lazenka MF, Sim-Selley LJ, Abdullah RA, Niphakis MJ, Vann RE, Cravatt BF, Wiley JL, Negus SS, Lichtman AH. Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice. J Pharmacol Exp Ther 2015;352:195-207. [PMID: 25398241 DOI: 10.1124/jpet.114.218677] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
41 Lile JA, Kelly TH, Hays LR. Substitution Profile of the Cannabinoid Agonist Nabilone in Human Subjects Discriminating Δ9-Tetrahydrocannabinol. Clinical Neuropharmacology 2010;33:235-42. [DOI: 10.1097/wnf.0b013e3181e77428] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
42 Goodwin RS, Gustafson RA, Barnes A, Nebro W, Moolchan ET, Huestis MA. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit 2006;28:545-51. [PMID: 16885723 DOI: 10.1097/00007691-200608000-00010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
43 Calakos KC, Bhatt S, Foster DW, Cosgrove KP. Mechanisms Underlying Sex Differences in Cannabis Use. Curr Addict Rep 2017;4:439-53. [PMID: 29503790 DOI: 10.1007/s40429-017-0174-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 7.8] [Reference Citation Analysis]
44 Banks ML, Negus SS. Insights from Preclinical Choice Models on Treating Drug Addiction. Trends Pharmacol Sci 2017;38:181-94. [PMID: 27916279 DOI: 10.1016/j.tips.2016.11.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 40] [Article Influence: 11.6] [Reference Citation Analysis]